Biotech entity
All 1 tracked stories fall under one category: pharma. iDose TR is most often covered alongside Glaukos Corporation, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention iDose TR, all published on February 21, 2026.
Last mentioned: Feb 21, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. iDose TR is most often covered alongside Glaukos Corporation, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention iDose TR, all published on February 21, 2026. Each carries 5 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering iDose TR. Shared-story counts are live from our verified record — not editorial picks.
Glaukos Corporation reported strong Q4 2025 results, driven by the rapid commercial adoption of its iDose TR sustained-release implant and a resilient MIGS franchise. The company's strategic shift toward dropless glaucoma therapies is yielding significant revenue growth and improved 2026 guidance.
iDose TR is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
